EUVIMEDEUVIMED entdecken
Crossref

TITE ‐ LOCRM12 : A Local Continual Reassessment Method for Drug Combination Optimization Based on Late‐Onset Toxicity and Efficacy Outcomes

Li Liu iD, Ruitao Lin iD, Nolan A Wages

Pharmaceutical Statistics · 2026

DOI: 10.1002/pst.70120 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Statistics, 2026. Verfasst von Li Liu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics, Virginia Commonwealth University, Richmond, Virginia, USA. Hauptthemen laut MEDLINE: Clinical Trials, Phase I as Topic, Research Design, Clinical Trials, Phase II as Topic, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The primary goal of Phase I/II combination trials is to identify the optimal biological dose combination (OBDC), defined as the dose combination that achieves the highest efficacy while maintaining an acceptable toxicity rate. Several designs have been proposed for such trials. Among them, the local continual reassessment method for Phase I/II trials (LOCRM12) performs well when compared with other model‐based methods in most of the scenarios studied. However, LOCRM12 assumes that both toxicity and efficacy outcomes are fully observed before enrolling the next cohort, an assumption that may not hold in real‐world settings, where late‐onset outcomes are increasingly common with the emergence of novel therapies such as molecularly targeted agents and immunotherapies. To address this limitation, we propose a time‐to‐event extension of LOCRM12 (TITE‐LOCRM12) that accommodates both late‐onset toxicity and efficacy outcomes. The local modeling framework, which uses data from neighboring dose combinations, is robust and efficient when data are sparse in complex combination settings. Simulation studies show that the proposed design can achieve a high percentage of correctly selecting the OBDC while maintaining a feasible trial duration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials, Phase I as TopicResearch DesignClinical Trials, Phase II as TopicAntineoplastic Combined Chemotherapy ProtocolsHumansTreatment OutcomeComputer SimulationModels, StatisticalDose-Response Relationship, DrugTime FactorsDrug Combinations

Stichwörter der Autor:innen

Bayesian adaptive designPhase I/II clinical trialscancerdrug combinationlate‐onset outcomes

Substanzen

Drug Combinations

Autor:innen und Institutionen

  • Department of Biostatistics, Virginia Commonwealth University, Richmond, Virginia, USA.
  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Massey Comprehensive Cancer Center, Richmond, Virginia, USA.

ORCID-Profile: Li Liu, Ruitao Lin

Zitieren

APA

Liu, L., Lin, R., & Wages, N. A. (2026). TITE ‐ LOCRM12 : A Local Continual Reassessment Method for Drug Combination Optimization Based on Late‐Onset Toxicity and Efficacy Outcomes. Pharmaceutical Statistics. https://doi.org/10.1002/pst.70120

Vancouver

Liu L, Lin R, Wages NA. TITE ‐ LOCRM12 : A Local Continual Reassessment Method for Drug Combination Optimization Based on Late‐Onset Toxicity and Efficacy Outcomes. Pharmaceutical Statistics. 2026. doi:10.1002/pst.70120

BibTeX
@article{Liu2026,
  author = {Liu, Li and Lin, Ruitao and Wages, Nolan A},
  title = {TITE ‐ LOCRM12 : A Local Continual Reassessment Method for Drug Combination Optimization Based on Late‐Onset Toxicity and Efficacy Outcomes},
  journal = {Pharmaceutical Statistics},
  year = {2026},
  doi = {10.1002/pst.70120}
}
Kostenlos starten →